News

TG Therapeutics Reports Impressive Growth and 2025 Outlook

TG Therapeutics Reports Impressive Growth and 2025 Outlook

TG Therapeutics Celebrates Milestones and Looks to the Future

In a significant announcement, TG Therapeutics, Inc. (TGTX) has shared its financial results for the fourth quarter and the entire year of 2024, highlighted by impressive revenue figures and ambitious targets for 2025. The company's net revenue for their flagship product, BRIUMVI, reached $103.6 million for the fourth quarter and totaled $310 million for the full year, reflecting remarkable growth.

Performance Breakdown for 2024

Michael S. Weiss, the Chairman and CEO of TG Therapeutics, expressed pride in the company’s performance, emphasizing the robust adoption of BRIUMVI by patients with relapsing forms of multiple sclerosis (MS). In addition, he noted enhancements in their patent portfolio through to 2042 and the initiation of new clinical trials, which includes testing for subcutaneous configurations of BRIUMVI.

Key Highlights of 2024

  • BRIUMVI generated an impressive U.S. net product revenue of $103.6 million in the fourth quarter and $310 million for the full year of 2024, marking an annual growth of approximately 250%.
  • The company secured three new patents for BRIUMVI, ensuring protection through 2042.
  • In partnership with Neuraxpharm, BRIUMVI has officially launched in Europe, broadening its reach in the market.

Research and Development Advancements

TG Therapeutics is not only focused on revenue growth but also on advancing its research and development. The company has initiated several studies showcasing the efficacy and safety of BRIUMVI in chronic diseases.

Presentation of Data

  • The company presented five-year data from its ongoing studies, indicating that 92% of patients treated with BRIUMVI maintained functional stability with minimal relapses.
  • In the ENHANCE trial, rapid infusions of BRIUMVI were well-tolerated, demonstrating the treatment's significance in clinical practice.

Pipeline and Future Plans for Growth

As part of its growth strategy, TG Therapeutics has outlined specific milestones for 2025, aiming for a total global revenue of approximately $540 million. This plan includes substantial investments in clinical trials and expanding its product offerings.

2025 Projections

  • The target for U.S. net product revenue for BRIUMVI is projected to be around $525 million for 2025.
  • Operational expenses are expected to be approximately $300 million, excluding non-cash items.
  • To enhance patient experience, pivotal programs focusing on subcutaneous formulations of ublituximab will commence.

Financial Overview for 2024

The company's fiscal health appears robust, reflecting significant improvements compared to the previous year. Gross product revenue constituted a large portion of the company’s earnings, demonstrating successful product commercialization.

Key Financial Figures

  • The total revenue for 2024 saw a substantial climb, showcasing the effectiveness of TG Therapeutics' marketing and distribution strategies.
  • Research and development costs amounted to around $94.3 million for the year, indicative of the company's commitment to innovation in therapies for B-cell diseases.
  • Net income for the full year of 2024 stood at approximately $23.4 million, a notable turnaround compared to a loss in the prior year.

Conclusion: A Promising Future for TG Therapeutics

As TG Therapeutics continues to build on its success with BRIUMVI and expands its pipeline, the outlook for 2025 and beyond appears highly promising. With a focus on research innovation and strategic partnerships, the company is well-positioned to address unmet needs in the treatment of various autoimmune disorders.

Frequently Asked Questions

What is BRIUMVI and its primary use?

BRIUMVI (ublituximab-xiiy) is a monoclonal antibody used to treat adults with relapsing forms of multiple sclerosis, aimed at reducing disability progression.

What were TG Therapeutics' revenue figures for 2024?

The company reported U.S. net revenue of $103.6 million in Q4 2024 and $310 million for the full year, representing substantial growth.

What are the company’s financial targets for 2025?

TG Therapeutics aims for a total global revenue of approximately $540 million, with a specific target of $525 million from BRIUMVI sales in the U.S.

How does TG Therapeutics plan to enhance its product offerings?

The company plans to launch pivotal programs for subcutaneous formulations of ublituximab and expand its clinical development efforts.

What developments did TG Therapeutics achieve in 2024?

The company secured additional patents for BRIUMVI, expanded its European market presence, and presented significant clinical trial data supporting the effectiveness of its therapies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 562

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 284

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 419

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 90

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 631

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 220

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 494

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 378

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 437

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading

Top 5 Most Recently Viewed Articles

CGI Elevates Its Cloud Solutions with AWS Premier Status

Updated Category News Views 210

CGI Achieves Amazon Web Services Premier Tier Status CGI (NYSE: GIB) has recently reached a significant milestone by being recognized as an Amazon Web Services (AWS) Premier Tier Services Partner. This distinction represents the highest level in the AWS Partner Network, showcasing CGI's dedication to providing top-notch IT and consulting services. With this status, CGI...

Continue Reading
Velo3D Stock Surge: Insider Moves and Contract Boost

Updated Category News Views 219

Velo3D Inc (NASDAQ:VELO) is on the rise, trading up 3.77% to $9.36 following buzz around insider transactions and a significant defense contract. The market's reaction points to investor enthusiasm, but is there substance behind the spike? Sharp Rebound After Recent Sell-Off: What’s Behind It? Just days ago, VELO shares took a nosedive despite the announcement of an...

Continue Reading
Empowering Lives: The Role of Genetic Screening in Cancer Prevention

Updated Category News Views 33

Empowering Lives Through Genetic Screening jscreen, a national non-profit public health initiative dedicated to preventing genetic diseases and cancer, is ramping up efforts to educate the public regarding the crucial benefits of proactive genetic screening. The organization is committed to ensuring accessibility and affordability of cancer genetic testing, offering...

Continue Reading
BigBear.ai Holdings Faces Investigation by National Law Firm

Updated Category News Views 279

Investigation Launched Against BigBear.ai Holdings Bragar Eagel & Squire, P.C., known for its commitment to representing shareholder rights, has announced an investigation into BigBear.ai Holdings, Inc. (BBAI). This inquiry is spurred by a class action lawsuit that raises serious allegations regarding the company's management and their adherence to fiduciary duties. The...

Continue Reading
BitMEX Unveils Exciting Trading Competition for Lunar New Year

Updated Category News Views 192

BitMEX Launches an Exciting Trading Competition for the Lunar New Year BitMEX, recognized as a pioneer in the crypto derivatives trading space, has announced its latest competition in celebration of the Lunar New Year. This competition, aptly named the 'Slither to Success Trading Competition,' has drawn interest from traders eager to seize the opportunity to win a share...

Continue Reading